The current state of molecular testing in the treatment of patients with solid tumors, 2019

Wafik S. El-Deiry, Richard M. Goldberg, Heinz Josef Lenz, Anthony F. Shields, Geoffrey T. Gibney, Antoinette R. Tan, Jubilee Brown, Burton Eisenberg, Elisabeth I. Heath, Surasak Phuphanich, Edward Kim, Andrew J. Brenner, John L. Marshall

Research output: Contribution to journalReview articlepeer-review

75 Scopus citations


The world of molecular profiling has undergone revolutionary changes over the last few years as knowledge, technology, and even standard clinical practice have evolved. Broad molecular profiling is now nearly essential for all patients with metastatic solid tumors. New agents have been approved based on molecular testing instead of tumor site of origin. Molecular profiling methodologies have likewise changed such that tests that were performed on patients a few years ago are no longer complete and possibly inaccurate today. As with all rapid change, medical providers can quickly fall behind or struggle to find up-to-date sources to ensure he or she provides optimum care. In this review, the authors provide the current state of the art for molecular profiling/precision medicine, practice standards, and a view into the future ahead.

Original languageEnglish (US)
Pages (from-to)305-343
Number of pages39
JournalCA Cancer Journal for Clinicians
Issue number4
StatePublished - Jul 1 2019


  • biomarkers
  • cancer
  • drug target
  • gene expression profiling
  • molecular profiling
  • molecular-targeted therapy
  • mutation
  • precision medicine
  • sequence analysis

ASJC Scopus subject areas

  • Hematology
  • Oncology


Dive into the research topics of 'The current state of molecular testing in the treatment of patients with solid tumors, 2019'. Together they form a unique fingerprint.

Cite this